• Basilea highlighted two marketed hospital anti-infectives, Cresemba and Zevtera, as its current revenue base.
• Cresemba in-market sales reached USD 782 million for April 2025 to March 2026, up 27% year-on-year, across 76 countries.
• Zevtera launched in the US in July 2025 via Innoviva Specialty Therapeutics, with US market exclusivity running to April 2034.
• Pipeline focus on late-stage anti-infectives, led by phase 3 programs for fosmanogepix and ceftibuten-ledaborbactam.
• Non-dilutive R&D funding totals about USD 440 million, including about USD 160 million for product development programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.